Clinical Trial Update: Study of Safety, Tolerability, and Efficacy of a Combination Treatment of LJN452 and CVC in Adult Patients With NASH and Liver Fibrosis [Phase 2]

View source ↗

Summary

Phase 2 study evaluating safety, tolerability, and efficacy of LJN452 combined with CVC in adult patients with non-alcoholic steatohepatitis (NASH) and liver fi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Liver Fibrosis
• Non-alcoholic Steatohepatitis

Drugs mentioned

• CVC
• LJN452

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Non-alcoholic Steatohepatitis (NASH) | Phase 2 | Status: COMPLETED | Results posted: 2021-11-12